Vebreltinib (also known as bozitinib) is a pharmaceutical drug used for the treatment of cancer.[1][2]
Vebreltinib selectively binds to c-Met, preventing its phosphorylation and thereby disrupting c-Met signal transduction pathways.[3]
In China, it is approved for the treatment of non-small-cell lung cancer (NSCLC) with MET exon 14 skipping mutations.[4]
^Hong L, Zhang J, Heymach JV, Le X (2021). "Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer". Therapeutic Advances in Medical Oncology. 13: 1758835921992976. doi:10.1177/1758835921992976. PMC 7890719. PMID 33643443.
^Han Y, Yu Y, Miao D, Zhou M, Zhao J, Shao Z, et al. (February 2024). "Targeting MET in NSCLC: An Ever-Expanding Territory". JTO Clinical and Research Reports. 5 (2): 100630. doi:10.1016/j.jtocrr.2023.100630. PMC 10867448. PMID 38361739.
^"Vebreltinib". NCI Drug Dictionary. U.S. National Institutes of Health.
^"Vebreltinib Receives Approval in China For MET Exon 14+ NSCLC". onclive.com. November 16, 2023.
Vebreltinib (also known as bozitinib) is a pharmaceutical drug used for the treatment of cancer. Vebreltinib selectively binds to c-Met, preventing its...
and AXL. Phase I clinical trial of MP470 had been announced in 2007. Vebreltinib, approved in China for the treatment of non-small-cell lung cancer. Since...